These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26977295)

  • 1. Anti-inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus-inducible cytokines.
    Edwards MR; Facchinetti F; Civelli M; Villetti G; Johnston SL
    Pharmacol Res Perspect; 2016 Feb; 4(1):e00202. PubMed ID: 26977295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients.
    Lea S; Metryka A; Li J; Higham A; Bridgewood C; Villetti G; Civelli M; Facchinetti F; Singh D
    Cytokine; 2019 Nov; 123():154739. PubMed ID: 31319374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.
    Moretto N; Caruso P; Bosco R; Marchini G; Pastore F; Armani E; Amari G; Rizzi A; Ghidini E; De Fanti R; Capaldi C; Carzaniga L; Hirsch E; Buccellati C; Sala A; Carnini C; Patacchini R; Delcanale M; Civelli M; Villetti G; Facchinetti F
    J Pharmacol Exp Ther; 2015 Mar; 352(3):559-67. PubMed ID: 25576075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells.
    Gianello V; Salvi V; Parola C; Moretto N; Facchinetti F; Civelli M; Villetti G; Bosisio D; Sozzani S
    Biochem Pharmacol; 2019 May; 163():371-380. PubMed ID: 30851246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients.
    Southworth T; Kaur M; Hodgson L; Facchinetti F; Villetti G; Civelli M; Singh D
    Cytokine; 2019 Jan; 113():68-73. PubMed ID: 29934047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases.
    Phillips JE
    Front Pharmacol; 2020; 11():259. PubMed ID: 32226383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD.
    Singh D; Beeh KM; Colgan B; Kornmann O; Leaker B; Watz H; Lucci G; Geraci S; Emirova A; Govoni M; Nandeuil MA
    Respir Res; 2019 Aug; 20(1):180. PubMed ID: 31399091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease.
    Facchinetti F; Civelli M; Singh D; Papi A; Emirova A; Govoni M
    Front Pharmacol; 2021; 12():740803. PubMed ID: 34887752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease.
    Moodley T; Wilson SM; Joshi T; Rider CF; Sharma P; Yan D; Newton R; Giembycz MA
    Mol Pharmacol; 2013 Apr; 83(4):894-906. PubMed ID: 23389862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.
    Villetti G; Carnini C; Battipaglia L; Preynat L; Bolzoni PT; Bassani F; Caruso P; Bergamaschi M; Pisano AR; Puviani V; Stellari FF; Cenacchi V; Volta R; Bertacche V; Mileo V; Bagnacani V; Moretti E; Puccini P; Catinella S; Facchinetti F; Sala A; Civelli M
    J Pharmacol Exp Ther; 2015 Mar; 352(3):568-78. PubMed ID: 25576073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis.
    Govoni M; Bassi M; Vezzoli S; Lucci G; Emirova A; Nandeuil MA; Petruzzelli S; Jellema GL; Afolabi EK; Colgan B; Leaker B; Kornmann O; Beeh KM; Watz H; Singh D
    Respir Res; 2020 Mar; 21(1):72. PubMed ID: 32197620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus.
    Skevaki CL; Christodoulou I; Spyridaki IS; Tiniakou I; Georgiou V; Xepapadaki P; Kafetzis DA; Papadopoulos NG
    Clin Exp Allergy; 2009 Nov; 39(11):1700-10. PubMed ID: 19549024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can Phosphodiesterase 4 Inhibitor Therapy Be Used in Respiratory Diseases Other Than Chronic Obstructive Pulmonary Disease?
    Goonathilake MR; Waqar S; George S; Jean-Baptiste W; Yusuf Ali A; Inyang B; Koshy FS; George K; Poudel P; Chalasani R; Mohammed L
    Cureus; 2022 Jul; 14(7):e27132. PubMed ID: 36017299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHF6001 Inhibits NF-κB Activation and Neutrophilic Recruitment in LPS-Induced Lung Inflammation in Mice.
    Stellari FF; Sala A; Ruscitti F; Buccellati C; Allen A; Risé P; Civelli M; Villetti G
    Front Pharmacol; 2019; 10():1337. PubMed ID: 31798449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superiority of combined phosphodiesterase PDE3/PDE4 inhibition over PDE4 inhibition alone on glucocorticoid- and long-acting β2-adrenoceptor agonist-induced gene expression in human airway epithelial cells.
    BinMahfouz H; Borthakur B; Yan D; George T; Giembycz MA; Newton R
    Mol Pharmacol; 2015 Jan; 87(1):64-76. PubMed ID: 25324049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
    Lipworth BJ
    Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tiotropium Attenuates Virus-Induced Pulmonary Inflammation in Cigarette Smoke-Exposed Mice.
    Bucher H; Duechs MJ; Tilp C; Jung B; Erb KJ
    J Pharmacol Exp Ther; 2016 Jun; 357(3):606-18. PubMed ID: 27016458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-inhalation of roflumilast, rather than formoterol, with fluticasone more effectively improves asthma in asthmatic mice.
    Murad HA; Habib HS; Rafeeq MM; Sulaiman MI; Abdulrahman AS; Khabaz MN
    Exp Biol Med (Maywood); 2017 Mar; 242(5):516-526. PubMed ID: 28056550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
    Hatzelmann A; Schudt C
    J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.